Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

46 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical efficacy of omalizumab in chronic spontaneous urticaria is associated with a reduction of FcεRI-positive cells in the skin.
Metz M, Staubach P, Bauer A, Brehler R, Gericke J, Kangas M, Ashton-Chess J, Jarvis P, Georgiou P, Canvin J, Hillenbrand R, Erpenbeck VJ, Maurer M. Metz M, et al. Among authors: canvin j. Theranostics. 2017 Mar 6;7(5):1266-1276. doi: 10.7150/thno.18304. eCollection 2017. Theranostics. 2017. PMID: 28435464 Free PMC article. Clinical Trial.
Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study.
Saini SS, Bindslev-Jensen C, Maurer M, Grob JJ, Bülbül Baskan E, Bradley MS, Canvin J, Rahmaoui A, Georgiou P, Alpan O, Spector S, Rosén K. Saini SS, et al. Among authors: canvin j. J Invest Dermatol. 2015 Jan;135(1):67-75. doi: 10.1038/jid.2014.306. Epub 2014 Jul 21. J Invest Dermatol. 2015. PMID: 25046337 Free PMC article. Clinical Trial.
Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria.
Maurer M, Rosén K, Hsieh HJ, Saini S, Grattan C, Gimenéz-Arnau A, Agarwal S, Doyle R, Canvin J, Kaplan A, Casale T. Maurer M, et al. Among authors: canvin j. N Engl J Med. 2013 Mar 7;368(10):924-35. doi: 10.1056/NEJMoa1215372. Epub 2013 Feb 24. N Engl J Med. 2013. PMID: 23432142 Free article. Clinical Trial.
Omalizumab in asthma: an update on recent developments.
Humbert M, Busse W, Hanania NA, Lowe PJ, Canvin J, Erpenbeck VJ, Holgate S. Humbert M, et al. Among authors: canvin j. J Allergy Clin Immunol Pract. 2014 Sep-Oct;2(5):525-36.e1. doi: 10.1016/j.jaip.2014.03.010. Epub 2014 Jun 11. J Allergy Clin Immunol Pract. 2014. PMID: 25213045 Review.
Efficacy and Safety of Omalizumab in Patients with Chronic Idiopathic/Spontaneous Urticaria who Remain Symptomatic on H1 Antihistamines: A Randomized, Placebo-Controlled Study.
Saini SS, Bindslev-Jensen C, Maurer M, Grob JJ, Bülbül Baskan E, Bradley MS, Canvin J, Rahmaoui A, Georgiou P, Alpan O, Spector S, Rosén K. Saini SS, et al. Among authors: canvin j. J Invest Dermatol. 2015 Mar;135(3):925. doi: 10.1038/jid.2014.512. Epub 2014 Dec 11. J Invest Dermatol. 2015. PMID: 25501032 Free article. No abstract available.
Omalizumab and the risk of malignancy: results from a pooled analysis.
Busse W, Buhl R, Fernandez Vidaurre C, Blogg M, Zhu J, Eisner MD, Canvin J. Busse W, et al. Among authors: canvin j. J Allergy Clin Immunol. 2012 Apr;129(4):983-9.e6. doi: 10.1016/j.jaci.2012.01.033. Epub 2012 Feb 23. J Allergy Clin Immunol. 2012. PMID: 22365654
46 results